Preeclampsia and IL-27: New Insights into Maternal Health
"Discover the crucial link between IL-27 levels and preeclampsia, a severe pregnancy complication, and how it could impact diagnosis and treatment."
Preeclampsia (PE) is a pregnancy-specific syndrome characterized by hypertension and proteinuria, typically arising after 20 weeks of gestation. Affecting 2-8% of pregnancies worldwide, PE remains a significant contributor to maternal and neonatal morbidity and mortality. Despite ongoing research, the precise causes and mechanisms underlying PE are not fully understood, highlighting the urgent need for improved diagnostic and therapeutic strategies.
Recent research has increasingly focused on the role of the immune system and inflammation in the development of PE. Rather than a controlled inflammatory response, PE is believed to involve an exaggerated maternal immune reaction to placental stimuli. This response is characterized by an imbalance in T helper cells (Th1 and Th2), leading to a cascade of inflammatory cytokine production. Cytokines like IL-1β, IL-6, IL-8, IL-12, TNF-α, and IFN-γ are often elevated in PE, while protective cytokines like IL-4, IL-5, and IL-10 are reduced, further disrupting the delicate balance required for a healthy pregnancy.
Interleukin-27 (IL-27), a member of the IL-12 cytokine family, has emerged as a key player in immune regulation. Composed of two subunits, EBI3 and IL-27p28, IL-27 is primarily produced by antigen-presenting cells (APCs). Its receptor, WSX-1/TCCR, is widely expressed on various immune cells, including T cells, B cells, NK cells, and even non-immune cells like endothelial cells and trophoblasts. Given its diverse effects on immune responses, researchers have begun to investigate the role of IL-27 in PE, aiming to uncover potential diagnostic and therapeutic targets.
Global Preeclampsia Burden
Preeclampsia affects approximately 2 to 8 percent of pregnancies worldwide, making it one of the most prevalent pregnancy complications. When considering the broader category of hypertensive disorders of pregnancy (HDPs) — which includes eclampsia and HELLP syndrome — the prevalence rises to 5 to 10 percent of all pregnancies globally. Women who enter pregnancy with pre-existing hypertension face a substantially elevated risk, with preeclampsia rates climbing to 5 to 7 percent compared to 1 to 2 percent in normotensive mothers. These statistics underscore the scale of preeclampsia as a global maternal health concern that demands ongoing research and clinical attention.
Screening, Prevention, and Gaps in Care
Current screening for preeclampsia relies on clinical risk assessment and early pregnancy biomarker models, with low-dose acetylsalicylic acid (aspirin) recommended for primary prevention in high-risk populations. Cell-free fetal DNA, originally developed for non-invasive prenatal testing, has been investigated as a potential predictive tool using blood specimens drawn around 12 weeks gestation. Despite these advances, researchers note that preeclampsia still lacks both reliable biomarkers and effective treatment strategies, representing significant gaps in clinical management. Additionally, postpartum preeclampsia remains under-researched, with prevalence estimates varying widely from less than 1 percent to nearly 28 percent after childbirth.
From Hippocrates to Modern Understanding
The earliest recorded definition of preeclampsia dates back to Hippocrates around 400 BC, marking over 2,400 years of medical engagement with this condition. In the second century AD, Soranus from Ephesus first described visual disturbances associated with pregnancy-related hypertension, and in 1855, A. von Graefe documented serous retinal detachment in affected patients. These early observations established the multisystemic nature of the disorder that would take centuries to fully appreciate. Today, preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies and is responsible for over 70,000 maternal deaths and 500,000 fetal deaths annually worldwide.
Unveiling the Link: IL-27 and Preeclampsia Severity
A recent study published in Cytokine delved into the relationship between maternal circulating IL-27 levels and preeclampsia, offering new insights into the disease's severity and potential diagnostic markers. The research, led by Danial Jahantigh and colleagues, involved 56 preeclamptic women, 21 healthy pregnant women, and 20 healthy non-pregnant women. The study measured IL-27 serum levels using ELISA assays to determine if any correlation existed between IL-27 levels and the presence or severity of preeclampsia.
- Severity Matters: IL-27 levels were notably higher in women with severe preeclampsia compared to those with mild preeclampsia, indicating that IL-27 levels could correlate with the severity of the disease.
- Timing is Key: Women with early-onset severe preeclampsia had significantly different IL-27 levels than gestation-matched healthy pregnancies, suggesting IL-27 could be involved in the early stages of severe PE.
- Fetal Growth: Although the study did not find a significant relationship between IL-27 levels and fetal growth restriction (FGR), the potential impact of IL-27 on placental function and fetal development warrants further investigation.
Current Research Landscape
Preeclampsia is characterized as a heterogeneous, multisystemic disorder defined by new-onset hypertension and proteinuria during the second half of pregnancy. Current research recognizes that preeclampsia encompasses a set of symptoms rather than a single causative factor, with multiple underlying pathways potentially driving the condition. Studies focusing on late-onset and term preeclampsia are exploring potential biomarkers that may improve prediction and enable earlier intervention. Regional research, including studies among Omani women, is contributing to understanding how prevalence patterns vary across populations. These investigations reflect a growing recognition that diverse diagnostic approaches may be needed to address preeclampsia across different clinical and demographic contexts.
Barriers to Early Detection and Treatment
Despite advances in understanding preeclampsia, challenges persist in early detection and effective management of this potentially life-threatening condition. When left untreated, preeclampsia can progress to cause liver and kidney damage, stroke, seizures, blood clotting disorders, and fluid accumulation in the lungs for affected mothers. Critical care management of severe cases, including eclampsia, requires invasive hemodynamic monitoring and often urgent delivery, underscoring the severity of treatment limitations. These complications highlight the urgent need for improved predictive tools, earlier intervention strategies, and more consistent clinical monitoring throughout pregnancy.
Subtypes, Demographics, and Outcomes
Comparative studies examining perinatal outcomes between preeclampsia and superimposed preeclampsia have found that rates of small-for-gestational age, stillbirth, and placental abruption are not significantly different between the two conditions. Research comparing early-onset and late-onset preeclampsia has identified differences in BNP levels that may help distinguish between these subtypes and inform targeted management. Notable disparities in preeclampsia rates also exist based on nativity and race: U.S.-born Black women have higher rates than their foreign-born counterparts, while U.S.-born White women show lower rates (7.1 percent) compared to foreign-born White women. These comparative findings suggest that environmental, socioeconomic, and biological factors interact in complex ways to influence preeclampsia risk across different populations.
Future Directions: IL-27 as a Therapeutic Target
The findings from this study open up new avenues for exploring IL-27 as a potential therapeutic target for preeclampsia. Understanding how IL-27 contributes to the inflammatory processes in PE could lead to the development of targeted therapies to modulate its activity, potentially reducing the severity of the disease and improving outcomes for both mother and child. Further research is crucial to elucidate the precise mechanisms by which IL-27 influences the pathogenesis of PE and to evaluate its potential as a diagnostic and therapeutic tool.
Expert Perspectives on Definition and Monitoring
Preeclampsia is a multi-system disorder unique to pregnancy, defined by new-onset high blood pressure and often significant proteinuria or end-organ damage. Experts have noted a longstanding lack of consistency in how preeclampsia is defined across research literature, complicating efforts to compare studies and establish unified treatment protocols. In response to these challenges, patient advocates and clinicians have stressed the critical need for increased blood pressure monitoring during pregnancy, particularly in cases where patients went weeks without having their blood pressure checked. Expert discussions continue to emphasize that despite being a common condition, preeclampsia poses serious and sometimes fatal risks that demand greater clinical vigilance.
Innovations in Diagnostics and Therapeutics
The preeclampsia therapeutics market is undergoing a structural shift driven by rising disease prevalence, evolving regulatory frameworks, and rapid innovation across diagnostics, therapeutics, and digital health platforms. In Australia, approximately 5 percent of women are diagnosed with preeclampsia, with 1 percent experiencing severe complications, and a new early-pregnancy blood test has shown promise in predicting those at highest risk. The American College of Obstetricians and Gynecologists notes that high blood pressure during pregnancy increases not only the risk of preeclampsia but also preterm birth, placental abruption, and cesarean delivery. These converging developments suggest a future in which earlier detection and more personalized interventions could substantially improve maternal and fetal outcomes.
Global Initiatives and Persistent Disparities
Global efforts to improve preeclampsia management have been advanced through initiatives such as the PREeclampsia – Eclampsia Monitoring, Prevention, and Treatment (PRE-EMPT) program, which aims to accelerate progress in resource-limited settings. Updated diagnostic criteria now allow preeclampsia to be established even in the absence of proteinuria when other specific end-organ symptoms are present, broadening the scope of clinical identification. Magnesium sulfate has proven superior to other anticonvulsants in reducing recurrent convulsions among women with eclampsia and is recommended for women with preeclampsia at risk of seizures. Despite these advances, preeclampsia remains poorly understood and continues to be a leading cause of maternal and fetal deaths worldwide, highlighting persistent systemic challenges in care delivery.
Affordable Interventions and Emerging Molecular Insights
Real-world studies have demonstrated that low-dose aspirin can meaningfully reduce recurrent preeclampsia, with a number needed to treat of just six to prevent one case. The cost-effectiveness of this intervention is striking: daily low-dose aspirin for the duration of one pregnancy costs approximately $4.00, making it one of the most accessible preventive measures available. Nursing education programs now incorporate preeclampsia as a key clinical case study, reflecting its importance in training the next generation of maternal health providers. Meanwhile, research into long noncoding RNA (lncRNA) expression patterns in preeclampsia placenta has revealed novel molecular signatures that may eventually inform new diagnostic or therapeutic approaches. Together, these findings illustrate how both simple, affordable interventions and cutting-edge molecular research are advancing the fight against preeclampsia.